Evidence map›Paper›PMID 39869653›Full record

Observational studyPLoS neglected tropical diseases2025

Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea.

Krufinta Bun, Benedict Mode, Melinda Susapu, Joyceline Salo, Catherine Bjerum, Michael Payne, Daniel Tisch, Makoto Sekihara, Emanuele Giorgi, Gary J Weil and 4 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04124250 (When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04124250 completednot on this map

When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to

TypeobservationalSponsorUniversity Hospitals Cleveland Medical CenterRan2019 to 2024Enrolled12,930ConditionsLymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic FilariasisArmsObservational
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Krufinta BunDepartment of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
Benedict ModeProvincial Health Department, Kokopo, East New Britain Province, Papua New Guinea.
Melinda SusapuPapua New Guinea Department of Health, Port Moresby, Papua New Guinea.
Joyceline SaloPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Catherine BjerumDepartment of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
Michael PayneDepartment of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
Daniel TischDepartment of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
Makoto SekiharaJapan International Cooperation Agency (JICA), Tokyo, Japan.
Emanuele GiorgiCentre for Health Informatics, Computing and Statistics, Lancaster University, Lancaster, United Kingdom.
Gary J WeilInfectious Diseases Division, Department of Medicine, Washington University, St. Louis, Missouri, United States of America.
Peter U FischerInfectious Diseases Division, Department of Medicine, Washington University, St. Louis, Missouri, United States of America.
Leanne RobinsonBurnet Institute, Melbourne, Victoria, Australia.
Moses LamanPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Christopher L KingDepartment of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.ORCID https://orcid.org/0000-0003-3873-7860

Funding

Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
NCATS NIH HHS UM1 TR004528
6 · The paper itself

Abstract

backgroundWHO recommends two annual rounds of mass drug administration (MDA) with ivermectin, diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis (LF) elimination in treatment naïve areas that are not co-endemic for onchocerciasis such as Papua New Guinea (PNG). Whether two rounds of MDA are necessary or sufficient and the optimal sampling strategies and endpoints for stopping MDA remain undefined. METHODS AND

findingsTwo cross-sectional studies were conducted at baseline (N = 49 clusters or villages) and 12 months after mass drug administration (MDA) with IDA (N = 47 villages) to assess lymphatic filariasis (LF) by circulating filarial antigenemia (CFA) and microfilariae (Mf). Before MDA, children aged 6-9 years (N~50) and those  ≥  10 years (N~50) in each village were randomly sampled. Before MDA, the population mean prevalence of LF in East New Britain Province (ENBP), Papua New Guinea, was estimated using population proportionate sampling (PPS, N = 30) to be 59/2,561 (2.3%) CFA positive and 14/2,561 (0.6%) Mf positive. No children were Mf positive. However, LF infection was highly heterogeneous; 8 villages (26.7%) had a CFA prevalence >2%, and 7 villages (23.3%) had an Mf prevalence >1%. To identify sentinel villages with LF in areas under-sampled by PPS, 19 additional villages suspected to have LF were sampled, with 15 (79%) having >2% CFA prevalence and 7 (38%) >1% Mf (range 1-22%). Twenty-four villages were evaluated before and after MDA in age-matched adults ( ≥  18 years). Treatment reduced CFA prevalence by 34% and Mf prevalence by 90%. Post-MDA model-based geostatistics efficiently selected an additional 23 villages, of which 20 (87%) had a CFA prevalence  >  2%. None of these villages had >1% Mf. Post-MDA, two of four districts had no villages with >1% Mf.

conclusionsModel-based geostatistics was more effective than PPS in sampling high-risk LF sites in a heterogeneous area. Low LF prevalence and partial reduction of CFA limit children's effectiveness as sentinels. A single round of high-coverage MDA with IDA achieved elimination targets in low-prevalence villages in PNG. Higher-prevalence areas will need additional MDA rounds, which could be targeted to smaller evaluation units to cut costs.

trial registrationClinicaltrials.gov NCT04124250.

Indexed as

AlbendazoleDiethylcarbamazineElephantiasis, FilarialFilaricidesIvermectinMass Drug AdministrationAdolescentAdultAnimalsAntigens, HelminthChildCross-Sectional StudiesFemaleHumansMalePapua New GuineaAlbendazoleAntigens, HelminthDiethylcarbamazineFilaricidesIvermectin

Identifiers

PMID39869653
PMCPMC11798438

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.